Recruiting
Phase 2

Sacituzumab Govitecan & Pembrolizumab

Sponsor:

Massachusetts General Hospital

Code:

NCT04230109

Conditions

Invasive Breast Cancer

Triple Negative Breast Cancer

ER-Negative Breast Cancer

PR-Negative Breast Cancer

HER2-negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan

Pembrolizumab

Study Details

Brief summary:

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC)

The names of the study drugs involved in this study is:

  • Sacituzumab govitecan (SG)
  • Pembrolizumab (combination therapy with SG)

Conditions

Invasive Breast Cancer

Triple Negative Breast Cancer

ER-Negative Breast Cancer

PR-Negative Breast Cancer

HER2-negative Breast Cancer

Study ID

NCT04230109

Start date

Jul 14, 2020

Status verified date

Jul, 2026

Completion date

Oct, 2029

Anticipated

Primary completion date

Oct, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Female or male patients ≥ 18 years of age.
  • Histologically confirmed diagnosis of invasive breast cancer, previously untreated.
  • Pre-and postmenopausal women are eligible to participate if not pregnant, not breastfeeding, and at least one of the following conditions applies:

  • Not a woman of childbearing potential (WOCBP) OR
  • A WOCBP who agrees to use effective contraceptive measures that have a failure rate of less than 1% per year from the initiation of treatment through at least 6 months b. after the last dose of study treatment. WOCBP must agree to 1 of the following contraceptive methods:

  • Complete abstinence from intercourse of reproductive potential, or
  • Consistent and correct use of 1 of the following methods of birth control:

  • Nonhormonal intrauterine device (IUD); Hormonal IUD in conjunction with a barrier method; Female sterilization (have had surgical bilateral oophorectomy with or; without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment; Vasectomy in the male partner (upon medical assessment of surgical success)
  • Male patients with female partners of childbearing potential must practice

  • Complete abstinence from intercourse of reproductive potential
  • Have a surgically successful vasectomy upon medical assessment, or
  • Use condoms plus partner use of a contraceptive method with a failure rate of <1% per year during treatment and until 3 months after last dose of study drug.
  • ECOG performance status = 0, 1 (Karnofsky ≥60%, see Appendix A)
  • Ability to understand and the willingness to sign a written informed consent form (ICF). Patient has signed the ICF prior to any screening procedures being performed and is able to comply with protocol requirements, including research biopsy.
  • Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:

  • Absolute neutrophil count (ANC) ≥ 1,500 per mm3
  • Platelets ≥ 100,000 per mm3
  • Hemoglobin ≥9.0 g/dL
  • PT-INR ≤1.5 x institutional ULN unless participant is receiving anticoagulant therapy as long as PT or aPPT is within therapeutic range of intended use of anticoagulants (for patients receiving pembrolizumab only).
  • Serum creatinine <1.5 mg/dL or creatinine clearance ≥50 mL/min (via the Cockcroft-Gault formula) for participants with creatinine levels above institutional upper limit of normal (ULN)
  • Adequate hepatic function (bilirubin ≤ 1.5 ULN, AST and ALT ≤ 2.5 X ULN and serum albumin > 3 g/dL).

Exclusion Criteria:

  • Participants currently receiving systemic therapy for any malignancy or having received systemic therapy for a malignancy in the preceding 3 years. (Concurrent endocrine therapy allowed in the adjuvant setting. Concurrent GnRH agonists allowed in any setting. Concurrent CDK4/6 inhibitor not allowed in any setting.)
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:

  • History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry.
  • History of cardiac failure, known cardiomyopathy (LVEF < 50%; new LVEF assessment is not specifically required for this trial), significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following: ---Known risk to prolong the QT interval or induce Torsade's de Pointes.; Uncorrected hypomagnesemia or hypokalemia; Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg. Higher blood pressure is permissible per discretion of treating physician; Bradycardia (heart rate <50 at rest), by ECG or pulse; On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF >470 screening ECG
  • Pregnant or breast-feeding women are excluded from this study because the safety of study medications is not established.
  • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to enrollment are eligible for this trial. Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to registration. Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Participants who are not good candidates for the study (as per investigator judgement)
  • History of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to sacituzumab govitecan.

Study Design

Enrollment

239 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Sacituzumab Govitecan (monotherapy cohort)

\- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

  • Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.
  • This can be followed by standard chemotherapy at the discretion of treating physician.

experimental: Sacituzumab Govitecan and Pembrolizumab (combination cohort)

\- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

  • Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.
  • Pembrolizumab via iv, predetermined dosage per protocol, IV, 1 day per each 21-day cycle, for 4 cycles.
  • This can be followed by standard chemotherapy at the discretion of treating physician.

Interventions

Sacituzumab Govitecan

Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)

Pembrolizumab

Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)

Primary outcome measure

  • Pathological complete response(pCR) rate with sacituzumab govitecan [ Time Frame: 12 Weeks ]

Central Contacts and Locations

Central contacts

Laura Spring, MD

617-726-6500LSPRING2@PARTNERS.ORG

Locations

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Sara Tolaney, MD, MPH

617-632-3800

Principal Investigator:

Sara Tolaney, MD, MPH

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Laura Spring, MD

617-726-6500LSPRING2@PARTNERS.ORG

Principal Investigator:

Laura Spring, MD

Massachusetts General Hospital - North Shore Cancer Center

Recruiting

Danvers, Massachusetts, United States, 01923

Contacts

Therese Mulvey, MD

978-882-6060

Principal Investigator:

Therese Mulvey, MD

Massachusetts General Hospital at Newton-Wellesley Hospital

Recruiting

Newton, Massachusetts, United States, 02462

Contacts

Amy Comander, MD

617-219-1230

Principal Investigator:

Amy Comander, MD

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Jul 17, 2026

Last verified

Jul, 2026

Keywords

  • Invasive Breast Cancer
  • Triple Negative Breast Cancer
  • ER-Negative Breast Cancer
  • PR-Negative Breast Cancer
  • HER2-negative Breast Cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-07-17.